Elara Capital sees GLP-1 drugs as a major tailwind for India’s pharma sector, potentially becoming first-line therapy for diabetes and obesity. The brokerage recommends buying five stocks, accumulating four others, and selling one amid shifting metabolic treatment trends globally ahead.